427 related articles for article (PubMed ID: 17441906)
1. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel angiogenesis inhibitors.
Sridhar J; Akula N; Sivanesan D; Narasimhan M; Rathinavelu A; Pattabiraman N
Bioorg Med Chem Lett; 2005 Sep; 15(18):4125-9. PubMed ID: 15993586
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies.
Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA
Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
6. Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening.
Dessalew N; Bharatam PV
Chem Biol Drug Des; 2006 Sep; 68(3):154-65. PubMed ID: 17062013
[TBL] [Abstract][Full Text] [Related]
7. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
[TBL] [Abstract][Full Text] [Related]
9. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
Lee K; Jeong KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
Eur J Med Chem; 2010 Nov; 45(11):5420-7. PubMed ID: 20869793
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
Vyas VK; Ghate M; Goel A
J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
[TBL] [Abstract][Full Text] [Related]
13. Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening.
Dessalew N; Bharatam PV
Biophys Chem; 2007 Jul; 128(2-3):165-75. PubMed ID: 17482749
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
[TBL] [Abstract][Full Text] [Related]
15. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.
Li HF; Lu T; Zhu T; Jiang YJ; Rao SS; Hu LY; Xin BT; Chen YD
Eur J Med Chem; 2009 Mar; 44(3):1240-9. PubMed ID: 18947905
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.
Peifer C; Selig R; Kinkel K; Ott D; Totzke F; Schächtele C; Heidenreich R; Röcken M; Schollmeyer D; Laufer S
J Med Chem; 2008 Jul; 51(13):3814-24. PubMed ID: 18529047
[TBL] [Abstract][Full Text] [Related]
17. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
[TBL] [Abstract][Full Text] [Related]
18. Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists.
Funk OF; Kettmann V; Drimal J; Langer T
J Med Chem; 2004 May; 47(11):2750-60. PubMed ID: 15139753
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
20. Structure-based virtual screening of Src kinase inhibitors.
Lee K; Kim J; Jeong KW; Lee KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
Bioorg Med Chem; 2009 Apr; 17(8):3152-61. PubMed ID: 19321350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]